Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on Glucose tolerance and ENdothelial function - a crossover Trial (AGENT)

Table 4 Comparison of laboratory data and PAT ratio between treatment with azelnidipine and amlodipine

	Baseline	Azelnidipine N = 17	Amlodipine N = 17	P**
TC, mg/dL	191 ± 17	194 ± 22	191 ± 23	0.617
LDL-C, mg/L	109 ± 19	111 ± 24	110 ± 19	0.730
HDL-C, mg/dL	57 ± 17	58 ± 18	57 ± 17	0.437
Triglyceride, mg/dL	104 ± 60	110 ± 57	114 ± 65	0.750
HbA1c, %	5.1 ± 0.3	5.1 ± 0.2	5.1 ± 0.3	0.999
hs-CRP, mg/L	1.14 ± 2.66	0.36 ± 0.23	0.74 ± 0.76	0.067
Interleukin-6, pg/mL	1.31 ± 0.61	1.44 ± 0.73	1.81 ± 0.77	0.035
eGFR, ml/min/1.73 m ²	83.2 ± 18.3	82.3 ± 16.1	79.4 ± 15.8	0.188
L-FABP/U-Cr, ng/g Cr	29.4 ± 40.0	13.9 ± 16.2	17.9 ± 16.9	0.187
Micro-alb/U-Cr, mg/g Cr	23.6 ± 47.4	26.6 ± 59.9	38.0 ± 87.4	0.120
HPC,/μL	2.79 ± 1.67	3.56 ± 1.59*	2.65 ± 1.17	0.016
PAT ratio	1.93 ± 0.34	2.05 ± 0.39	2.11 ± 0.47	0.587

Data are mean ± SD. TC; total cholesterol, LDL-C; low-density lipoprotein cholesterol, HDL-C; high-density lipoprotein cholesterol, Hb; hemoglobin, hs-CRP; high sensitivity C-reactive protein, BNP; brain natriuretic peptide, eGFR; estimated glomerular filtration ratio, GFR(ml/min/1.73 m²) L-FABP, L-type fatty acid binding protein, alb; albuminuria, U-Cre; urine creatinine, HPC; hematopoietic progenitor cell, PAT: peripheral arterial tonometry. * P < 0.05 vs. baseline. ** azelnidipine vs. amlodipine.

ISSN: 1475-2840